SEC Comment Letter for Dianthus Therapeutics, (DNTH) — Aug 12, 2019
Dianthus Therapeutics, Inc. /DE/ (DNTH) (CIK 0001690585)
Date: Aug. 12, 2019 · CIK: 0001690585 · Accession: 0000000000-19-012296
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233127
Letter
August 9, 2019 Jason Gardner Chief Executive Officer Magenta Therapeutics, Inc. 100 Technology Square Cambridge, MA 02139 Re:Magenta Therapeutics, Inc. Registration Statement on Form S-3 Filed August 8, 2019 File No. 333-233127 Dear Mr. Gardner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Donald Field at 202-551-3680 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
August 9, 2019
Jason Gardner
Chief Executive Officer
Magenta Therapeutics, Inc.
100 Technology Square
Cambridge, MA 02139
Re:Magenta Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 8, 2019
File No. 333-233127
Dear Mr. Gardner:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Donald Field at 202-551-3680 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance